TB-500 (Thymosin Beta-4): Uses, Evidence, and What to Know
TB-500 is one of the most commonly used recovery peptides in both athletic communities and functional medicine clinics ā often paired with BPC-157, and sometimes referred to almost interchangeably with it. But TB-500 and BPC-157 are distinct compounds with different origins, different mechanisms, and importantly, different evidence profiles. TB-500 has a small but meaningful human trial record that BPC-157 currently lacks.
This guide covers what TB-500 actually is, how it differs from its full parent molecule (Thymosin Beta-4), what the human evidence shows, why competitive athletes face strict consequences for using it, and what an honest assessment of its risk profile looks like in 2026.
Key Takeaways
- TB-500 is a synthetic 7-amino-acid fragment of Thymosin Beta-4 ā a protein naturally present in virtually every cell in the human body except red blood cells.
- Its primary mechanism is actin sequestration, which drives cell migration, tissue repair, and new blood vessel formation.
- Unlike BPC-157, TB-500 acts systemically ā it circulates and concentrates at injury sites throughout the body, not just near the injection site.
- Phase II human clinical trials have been completed for wound healing (venous stasis ulcers, pressure sores, epidermolysis bullosa) with modest positive results ā making it one of the few non-GLP-1 recovery peptides with any randomised human trial data.
- TB-500 has been on the WADA Prohibited List since 2011 under Section S2 (Growth Factors and Growth Factor Modulators). Sanctions are significant.
- Thymosin Beta-4 levels are elevated in some metastatic cancers ā an important consideration for patients with cancer history.
TB-500 vs Thymosin Beta-4: An Important Distinction
Understanding TB-500 requires distinguishing it from the molecule it derives from. Thymosin Beta-4 (TĪ²4) is a naturally occurring 43-amino-acid protein found in almost every mammalian cell, with particularly high concentrations in platelets, white blood cells, plasma, and wound fluid. It was first isolated from calf thymus tissue in 1981 by Dr. Allan Goldstein and colleagues at the National Institutes of Health, and has been studied continuously since.[1]
TB-500 is not the same as Thymosin Beta-4. It is a synthetic fragment of TĪ²4 ā specifically the 7-amino-acid sequence at positions 17ā23 (Ac-LKKTETQ). This particular region is considered the active core of TĪ²4's biological activity: the G-actin binding domain that drives cell migration, wound healing, and angiogenesis. By isolating and synthesising this fragment, researchers created a more stable, injectable compound that retains the key functional properties of the full molecule in a more practical form.
How TB-500 Works: The Actin Mechanism
TB-500's primary mechanism centres on actin regulation ā a cellular function that is fundamental to how tissue heals. Actin is a structural protein that forms the internal scaffolding of cells, and it plays an essential role in cell movement, division, and contraction. By binding to G-actin (the soluble, monomeric form of actin), TB-500 influences the balance between the free and polymerised forms of actin inside cells ā a process that has cascading effects on cellular behaviour.[2]
How TB-500 Differs from BPC-157
Because TB-500 and BPC-157 are frequently used together and often discussed interchangeably, understanding how they differ is clinically important:
- 15-amino-acid gastric peptide
- Mechanism: VEGFR2, nitric oxide, anti-inflammatory
- Acts more locally ā often injected near injury site
- Strong GI repair and gastroprotective effects
- 35/36 human studies preclinical; 4 human pilot studies
- Shorter preclinical history of WADA prohibition
- No Phase II RCT data in wound healing
- 7-amino-acid fragment of Thymosin Beta-4
- Mechanism: actin binding, cell migration, angiogenesis
- Acts systemically ā concentrates at injury sites regardless of injection location
- Broader cardiac and neurological repair research
- Phase II RCT data in venous stasis ulcers and pressure wounds
- WADA prohibited since 2011 ā longer enforcement history
- No FDA approval for any indication
These differences inform why they are often combined: the two peptides target overlapping but distinct molecular pathways, and their different modes of distribution (local vs systemic) provide complementary coverage for musculoskeletal injuries.[3]
The Human Evidence: Phase II Trials and Early Studies
TB-500's evidence profile differs meaningfully from BPC-157 in one important respect: Phase II randomised controlled trials in human patients have been completed ā specifically for wound healing indications. This does not mean the evidence is comprehensive or sufficient for FDA approval, but it does represent a higher standard of evidence than most of the other recovery peptides discussed in this hub.
| Study | Population | Design | Key Finding | Limitation |
|---|---|---|---|---|
| Venous stasis ulcer trial | n=73, Europe (8 sites) | Double-blind, placebo-controlled Phase II RCT | 0.03% topical TĪ²4 led to complete healing in ~25% of patients within 3 months, primarily small-to-moderate wounds; accelerated healing by ~1 month in some | Overall healing rates not conclusively superior to control; small sample; no Phase III follow-on |
| Pressure ulcer / epidermolysis bullosa trial | 143 patients | Phase II RCT | TĪ²4 accelerated healing by approximately one month in patients who healed; acceptable safety profile | Not all patients responded; no Phase III completed |
| Dry eye study | n=9 | Pilot | 35% reduction in discomfort; 59% improvement in dry eye parameters; increased tear production after 56 days of TĪ²4 eye drops | Very small; no placebo control |
| Cardiac pilot (endothelial progenitor cells) | Acute STEMI patients | Safety and efficacy pilot | TĪ²4 pre-treated endothelial progenitor cell transplantation showed acceptable safety; modest cardiac function signals | Very small; exploratory; not powered for efficacy |
| Healthy adult safety study | Healthy adults | Safety assessment | Safety profile deemed acceptable; no significant adverse events identified | Details not fully published; sample size not specified in accessible literature |
The most important takeaway from the wound healing trials: the results were modestly positive for a subset of patients but not definitively superior to placebo in overall healing rates. This is a meaningful distinction. It suggests biological activity is present and some patients benefit meaningfully ā but the effect is not uniform or large enough to have advanced to Phase III trials. The development programme for TĪ²4 as a wound healing drug (under the name RGN-137) has not progressed to approval.[4]
Tissue Applications: Where the Evidence Points
Evidence Strength by Application Area
The Systemic Action Advantage ā and Its Implications
One of TB-500's most clinically relevant properties is its systemic distribution. Unlike BPC-157, which is often injected subcutaneously near the injured area to maximise local concentration, TB-500 circulates throughout the body and preferentially accumulates at sites of active tissue damage. The biological rationale is consistent with Thymosin Beta-4's natural role: the body's wound fluid contains high concentrations of TĪ²4 precisely because it is mobilised to wherever damage has occurred.
In practical terms, this means patients with multiple concurrent injuries, or injuries in difficult-to-reach anatomical locations, may benefit from TB-500's systemic distribution in ways that locally-administered peptides cannot match. It is also one reason why TB-500 has attracted interest in conditions as diverse as cardiac repair and spinal cord injury in animal models ā the peptide can reach tissues that would be difficult to treat with targeted local injection.
This systemic distribution also carries an important implication for the cancer risk consideration. Because TB-500 reaches all tissues ā not just a targeted site ā its angiogenic effects are not confined to the injury. This amplifies the concern that patients with any existing tumour burden, dormant cancer cells, or precancerous lesions could see accelerated growth through the same vascular support that the peptide provides to healing tissue.[5]
Regulatory Status and WADA
TB-500 Regulatory Status (as of April 2026)
Safety Profile: What We Know
The animal safety record for Thymosin Beta-4 is generally favourable across the extensive preclinical literature. The Phase II human trials reported acceptable safety profiles with no significant adverse events. The cardiac pilot study found no safety concerns with TB-500 pre-treatment. And the healthy adult safety study reported no significant issues.
The principal safety concern that warrants explicit discussion is the relationship between Thymosin Beta-4 and cancer. Research has documented that TĪ²4 levels are elevated in some metastatic cancers ā particularly ovarian, colorectal, and breast cancers ā where its cell migration and angiogenic properties may contribute to tumour invasiveness and progression. This is not evidence that administering TB-500 causes cancer in otherwise healthy people. It is evidence that the biological mechanisms TB-500 activates are the same ones that cancers exploit to grow and spread.
For patients with active cancer, recent cancer history, or a family history of cancers associated with angiogenesis or tissue invasion, this concern is clinically significant. Any clinician prescribing TB-500 in these populations should conduct a thorough assessment and document informed consent regarding this theoretical risk.[5]
How TB-500 Is Typically Used in Practice
In clinical practice, TB-500 protocols typically follow a loading-and-maintenance approach, based on animal study extrapolation and community experience rather than validated human dosing guidelines. A common structure involves:
- Loading phase: 4ā6mg per week (typically split into two injections) for 4ā6 weeks during an active injury or recovery period
- Maintenance phase: 2mg or less per week, often once weekly, as ongoing support
- Route: Subcutaneous injection ā injection site does not need to be proximal to the injury given systemic distribution
- Combination use: Frequently used alongside BPC-157, the rationale being complementary but non-overlapping mechanisms
These are community- and clinician-derived protocols, not FDA-validated doses. No established human dosing guidelines exist. Anyone considering TB-500 should have a clinician determine the protocol based on their individual circumstances, not follow generic online recommendations.
Summary Assessment
TB-500 is better evidenced than most recovery peptides at the human level ā Phase II trial data exists for wound healing, the safety profile in both animal and early human studies is acceptable, and the mechanisms are well-characterised. But "better evidenced than most" does not mean "adequately evidenced for routine clinical use." No Phase III trials have been completed, no FDA approval has been sought or granted, and the WADA prohibition is strict and longstanding. For patients not subject to competitive sport rules who are considering TB-500 under medical supervision, an honest framing is: this is a compound with genuine biological rationale and early human data, used ahead of the comprehensive evidence base that would justify it as a standard treatment.
Interested in recovery peptides under medical supervision?
Our free quiz helps you understand your options before speaking with a clinician.
Take Our Peptide Plan Quiz āReferences
- Maar K, et al. Utilizing Developmentally Essential Secreted Peptides Such as Thymosin Beta-4 to Remind the Adult Organs of Their Embryonic State. Cells. 2021;10(6):1343. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8228050/
- Sosne G, Kleinman HK. Primary Mechanisms of Thymosin Ī²4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries. Invest Ophthalmol Vis Sci. 2015;56(9):5110ā5117. Available from: https://iovs.arvojournals.org
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. J Invest Dermatol. 1999;113(3):364ā368. Available from: https://pubmed.ncbi.nlm.nih.gov/10469335/
- Liu J, et al. Progress on the Function and Application of Thymosin Ī²4. PMC. 2022. Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC8724243/
- BSCG. TB-500: Status, Risks, and Bans in Sport and Military. February 2026. Available from: https://www.bscg.org
- World Anti-Doping Agency. Prohibited List 2025. WADA. Available from: https://www.wada-ama.org/en/prohibited-list
- Ho EN, et al. Doping control analysis of TB-500, a synthetic version of an active region of thymosin beta(4), in equine urine and plasma. J Chromatogr A. 2012;1265:57ā69. Available from: https://pubmed.ncbi.nlm.nih.gov/23089241/